{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.55","upperLimit":"46.95","value":"22.3"},{"groupId":"OG001","lowerLimit":"7.20","upperLimit":"49.77","value":"18.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"description":"Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are objective responders","dispersionType":"Full Range","groups":[{"description":"Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg","id":"OG000","title":"Fulvestrant + Anastrozole"},{"description":"Anastrozole 1 mg","id":"OG001","title":"Anastrozole"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}